Researchers are studying the link between amyloid β (Aβ) in the brains of people with mild cognitive impairment (MCI) and Alzheimer's disease.
Mild Cognitive Impairment (MCI is a brain condition where the brain's cognitive functions are impaired beyond what is expected based on the age and education of the individual. It is usually considered a mild form of dementia. 10% to 20% of MCI go on to develop Alzheimer's disease.
The amount of amyloid β (Aβ) in the brains of people with mild cognitive impairment (MCI) is contributing to early memory loss, and increases with severity of symptoms, finds a study in BioMed Central's open access journal Alzheimer's Research & Therapy. The non-invasive study which used 18F-florbetaben to find Aβ plaques in brain scans to also show that in MCI the affect of Aβ on memory loss is independent of other aspects of mental decline.
Video: Dementia and Mild Cognitive Impairment
Positron emission tomography (PET) has previously relied on carbon-11 labeling of Aβ, however this study uses 18F-florbetaben which can be used for longer and allow more patients to be scanned at lower cost. A higher than normal amount of Aβ was found in half of the PET scans of people with MCI. Interestingly there was a strong association between Aβ and memory loss, but not with other features of neurodegeneration, such as hippocampal atrophy or the white matter hyperintensities frequently seen on MRI later in the development of Alzheimer's disease.
Prof Christopher Rowe, from Austin Health, Australia and the University of Melbourne, who led the study explained why it is important, "MCI is thought to affect between one in five and one in ten of all adults over the age of 65, and, although some of these will go on to develop dementia within a few years, the majority can lead a relatively normal life. Detection of Aβ plaques in MCI indicates early Alzheimer's disease, while a negative scan eliminates this possibility. Consequently a negative scan is very reassuring while a positive scan can lead to earlier and more appropriate medical and social management."
Mild Cognitive Impairment (MCI is a brain condition where the brain's cognitive functions are impaired beyond what is expected based on the age and education of the individual. It is usually considered a mild form of dementia. 10% to 20% of MCI go on to develop Alzheimer's disease.
The amount of amyloid β (Aβ) in the brains of people with mild cognitive impairment (MCI) is contributing to early memory loss, and increases with severity of symptoms, finds a study in BioMed Central's open access journal Alzheimer's Research & Therapy. The non-invasive study which used 18F-florbetaben to find Aβ plaques in brain scans to also show that in MCI the affect of Aβ on memory loss is independent of other aspects of mental decline.
Video: Dementia and Mild Cognitive Impairment
Positron emission tomography (PET) has previously relied on carbon-11 labeling of Aβ, however this study uses 18F-florbetaben which can be used for longer and allow more patients to be scanned at lower cost. A higher than normal amount of Aβ was found in half of the PET scans of people with MCI. Interestingly there was a strong association between Aβ and memory loss, but not with other features of neurodegeneration, such as hippocampal atrophy or the white matter hyperintensities frequently seen on MRI later in the development of Alzheimer's disease.
Prof Christopher Rowe, from Austin Health, Australia and the University of Melbourne, who led the study explained why it is important, "MCI is thought to affect between one in five and one in ten of all adults over the age of 65, and, although some of these will go on to develop dementia within a few years, the majority can lead a relatively normal life. Detection of Aβ plaques in MCI indicates early Alzheimer's disease, while a negative scan eliminates this possibility. Consequently a negative scan is very reassuring while a positive scan can lead to earlier and more appropriate medical and social management."
RELATED LINKS
8F-florbetaben Aβββ imaging in mild cognitive impairment
BioMed Central
Breakthrough in Fight Against Alzheimer's Disease
Eating Food Rich In Omega-3 Fatty Acids Such As Fish, Chicken, and Nuts Lowers Risk of Alzheimer's Disease
Daily Exercise And Physical Activity May Reduce Risk of Alzheimer's Disease
Alzheimer's Disease Risk Minimized by Eating Fish
Spin Labeled Fluorene Compounds - Molecules That Can Aid In Prevention And Delay of Alzheimer's Disease
Drug Controls Brain Inflammation to Treat Alzheimer's, Parkinson's, Multiple Sclerosis, and Traumatic Brain Injury
Study Reiterates Position That Ginkgo Biloba Has No Significant Effect Against Alzheimer's Disease